Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Bone ; 145: 115837, 2021 04.
Article in English | MEDLINE | ID: mdl-33385614

ABSTRACT

The bone encasing the inner ear, known as the otic capsule, is unique because it remodels little postnatally compared to other bones in the body. Previous studies established that osteoprotegerin (OPG) in the inner ear inhibits otic capsule remodeling. OPG acts as a decoy receptor of receptor activator of nuclear factor κB ligand (RANKL) to disrupt the interaction between RANKL and RANK, the primary regulators of bone metabolism. Here we studied the expression and function of RANK and RANKL in the murine cochlea. Using a combination of in situ hybridization, real-time quantitative RT-PCR, and western blot, we demonstrate that Rankl and Rank genes and their protein products are expressed in the intracochlear soft tissues and the otic capsule in a developmentally regulated manner. Using a culture of neonatal murine cochlear neurons, we show that the interaction between RANK and RANKL inhibits neurite outgrowth in these neurons, and is associated with upregulation of NOGO-A expression. Taken together, our results suggest that, in addition to regulating otic capsule bone remodeling, RANK and RANKL expressed by intracochlear soft tissues may also regulate spiral ganglion neuron function by affecting neurite outgrowth.


Subject(s)
Ear, Inner , RANK Ligand , Animals , Bone Remodeling , Mice , Nogo Proteins , Osteoprotegerin/genetics , Receptor Activator of Nuclear Factor-kappa B
2.
Aging Cell ; 15(2): 301-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26791792

ABSTRACT

Tumor necrosis factor (TNF) family cytokines are important mediators of inflammation. Elevated levels of serum TNF-α are associated with human sensorineural hearing loss via poorly understood mechanisms. We demonstrate, for the first time, expression of TNF-related apoptosis-inducing ligand (TRAIL) and its signaling death receptor 5 (DR5) in the murine inner ear and show that exogenous TRAIL can trigger hair cell and neuronal degeneration, which can be partly prevented with DR5-blocking antibodies.


Subject(s)
Hair Cells, Auditory, Inner/metabolism , Hearing Loss, Sensorineural/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , TNF-Related Apoptosis-Inducing Ligand/metabolism , Animals , Cochlea/metabolism , Cochlea/pathology , Ear, Inner/metabolism , Ear, Inner/pathology , Hair Cells, Auditory, Inner/pathology , Hearing Loss, Sensorineural/genetics , Hearing Loss, Sensorineural/therapy , Immunohistochemistry , In Situ Hybridization, Fluorescence , Mice , Mice, Inbred C57BL , Receptors, TNF-Related Apoptosis-Inducing Ligand/biosynthesis , Recombinant Proteins/pharmacology , Signal Transduction , Spiral Ganglion/metabolism , Spiral Ganglion/pathology , TNF-Related Apoptosis-Inducing Ligand/genetics , TNF-Related Apoptosis-Inducing Ligand/pharmacology
3.
Hear Res ; 265(1-2): 83-9, 2010 Jun 14.
Article in English | MEDLINE | ID: mdl-20146935

ABSTRACT

Our long term goal is to understand the molecular pathology of otosclerosis and to develop better forms of therapy. Toward this goal, the current study focused on characterizing the molecular factors responsible for the unique biological features of the otic capsule: its minimal rate of remodeling, and lack of healing capacity when fractured. We compared expression levels of 62 genes involved in bone metabolism between the adult murine otic capsule and the tibia and parietal bones; the latter exemplify bones formed by endochondral and intramembranous ossification, respectively. Gene expression levels were measured using real-time quantitative RT-PCR and analyzed using tools of bioinformatics. Expression patterns of key genes were verified with in situ hybridization. The molecular profile of the otic capsule was distinctly different from that of the tibia and parietal bone. Genes found to be most characteristic of the otic capsule were: osteoprotegerin (opg), bone morphogenetic protein receptor 1b (bmpr1b) and bone morphogenetic protein 3 (bmp3). Expression levels were high for opg and bmpr1b, and minimal for bmp3 within the otic capsule. We concluded that opg and bmpr1b likely play important roles in inhibition of remodeling within the otic capsule.


Subject(s)
Bone Remodeling/genetics , Ear, Inner/chemistry , Gene Expression Regulation , Parietal Bone/chemistry , RNA, Messenger/analysis , Tibia/chemistry , Animals , Bone Morphogenetic Protein 3/genetics , Bone Morphogenetic Protein Receptors, Type I/genetics , Computational Biology , Gene Expression Profiling/methods , In Situ Hybridization , Mice , Mice, Inbred C57BL , Osteoprotegerin/genetics , Polymerase Chain Reaction
4.
Audiol Neurootol ; 12(5): 334-43, 2007.
Article in English | MEDLINE | ID: mdl-17595534

ABSTRACT

Type I osteogenesis imperfecta (OI) is a disorder of skeletal bones characterized by bone fragility and blue sclera, which can result from mutations in genes encoding for type I collagen--the COL1A1 and COL1A2 genes. Fifty percent of patients with type I OI develop hearing loss and associated histopathological changes in the otic capsule that are indistinguishable from otosclerosis, a major cause of acquired hearing loss. In an attempt to elucidate molecular and cellular mechanisms of hearing loss in type I OI, we have studied the Mov13 mouse, which has served as an animal model of type I OI by virtue of exhibiting variable transcriptional block of the COL1A1 gene. We studied the morphometry of the Mov13 otic capsule and compared expression levels of 60 genes in the otic capsule with those in the tibia and parietal bone of the Mov13 and wild-type mice. The degree of transcriptional block of the COL1A1 gene and its downstream effects differed significantly between the bones examined. We found that expression levels of bone morphogenetic protein 3 and nuclear factor kappa-B1 best distinguished Mov13 otic capsule from wild-type otic capsule, and that osteoprotegerin, caspase recruitment domain containing protein 1, and partitioning defective protein 3 best distinguished Mov13 otic capsule from Mov13 tibia and parietal bone. Although the Mov13 mouse did not demonstrate evidence of active abnormal otic capsule remodeling as seen in type I OI and otosclerosis, studying gene expression in the Mov13 mouse has provided evidence that osteocytes of the otic capsule differ from osteocytes in other bones.


Subject(s)
Collagen Type I/genetics , Osteocytes/physiology , Osteogenesis Imperfecta/genetics , Temporal Bone/anatomy & histology , Animals , Collagen/genetics , Collagen Type I, alpha 1 Chain , Disease Models, Animal , Ear, Inner/anatomy & histology , Genetic Carrier Screening , Mice , Mice, Inbred C57BL
5.
Adv Otorhinolaryngol ; 65: 68-74, 2007.
Article in English | MEDLINE | ID: mdl-17245026

ABSTRACT

Otosclerosis is a bone disease of the human otic capsule, which is among the most common causes of acquired hearing loss. The pathologic process is characterized by a wave of abnormal bone remodeling in specific sites of predilection within the endochondral layer of the temporal bone. Although the cause of otosclerosis remains uncertain, there is a clear genetic predisposition with half of all cases occurring in families with more than one affected member. There is also compelling evidence that measles virus may play a role in some cases. Ultimately, how genetic factors and viral infection result in otosclerosis must be explained by effects on the molecular factors that control bone remodeling.


Subject(s)
Otosclerosis/genetics , Bone Remodeling/genetics , Cartilage/pathology , Ear, Middle/pathology , Gene Expression/physiology , Genetic Predisposition to Disease/genetics , Humans , Measles virus/genetics , Osteoblasts/pathology , Osteoprotegerin/genetics , Otosclerosis/pathology , RANK Ligand/genetics , RNA, Viral/genetics , Receptor Activator of Nuclear Factor-kappa B/genetics , Temporal Bone/pathology
6.
Laryngoscope ; 116(2): 201-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16467704

ABSTRACT

OBJECTIVES: The otic capsule, when compared with other bones in the body, is unique in that it undergoes no significant remodeling of bone after development. We previously demonstrated that osteoprotegerin (OPG), which inhibits formation and function of osteoclasts, is produced at high levels in the inner ear of normal mice and secreted into the perilymph from where it diffuses into the surrounding otic capsule bone through a lacunocanalicular system. To test our hypothesis that the high level of OPG may be important in the inhibition of otic capsule remodeling, we studied the light microscopic histology of the otic capsule in OPG knockout mice for evidence of abnormal remodeling of bone. We also tested the hearing in OPG knockout mice to determine whether OPG and its influence on surrounding bone is important for auditory function. METHODS: Temporal bone histopathology and pathophysiology were compared in homozygous OPG knockout mice and C57BL/6 (B6) mice, the background strain for the knockouts. Auditory function in age-matched animals from each group was evaluated at approximately 4-week intervals from 8 to 21 weeks using frequency-specific auditory brainstem responses (ABR) and distortion product otoacoustic emissions (DPOAE). After each of the last three evaluations, the cochleae from one mouse of each group were harvested, processed, and examined by light microscopy. RESULTS: Osteoprotegerin knockout mice demonstrated abnormal remodeling of bone within the otic capsule with multiple foci showing osteoclastic bone resorption and formation of new bone. Such changes were not seen in the age-matched B6 controls. The active bone remodeling process in the knockout animals showed many similarities to otosclerosis seen in human temporal bones. Over the time period that we monitored, auditory function was significantly and progressively compromised in the knockout animals relative to B6 controls. At the earliest age of test (8 wk), the loss was apparent as a mild, high-frequency reduction in sensitivity by ABR. In contrast, DPOAE losses in the knockouts were substantial even at 8 weeks, and by 21 weeks, these losses exceeded our equipment limits. Results of ABR testing showed hearing sensitivity changes in the animals of the background strain were confined largely to the high frequencies, whereas OPG knockouts demonstrated substantial low-frequency shifts in addition to those at high frequencies. CONCLUSIONS: The histopathological and pathophysiological findings in OPG knockout mice support the hypothesis that OPG is important in the inhibition of bone remodeling within the otic capsule and the maintenance of normal auditory function. This mouse may provide a valuable animal model of human otosclerosis.


Subject(s)
Bone Remodeling/physiology , Glycoproteins/physiology , Hearing Loss/physiopathology , Receptors, Cytoplasmic and Nuclear/physiology , Receptors, Tumor Necrosis Factor/physiology , Temporal Bone/physiopathology , Acoustic Stimulation , Animals , Bone Remodeling/genetics , Disease Models, Animal , Disease Progression , Ear, Inner/physiopathology , Evoked Potentials, Auditory, Brain Stem , Glycoproteins/deficiency , Glycoproteins/genetics , Hearing Loss/diagnosis , Mice , Mice, Inbred C57BL , Mice, Knockout , Osteoprotegerin , Receptors, Cytoplasmic and Nuclear/deficiency , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Tumor Necrosis Factor/deficiency , Receptors, Tumor Necrosis Factor/genetics
7.
Arch Otolaryngol Head Neck Surg ; 131(11): 1007-13, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16301374

ABSTRACT

OBJECTIVE: To determine the distribution of alpha1, alpha3, and alpha5 chains of type IV collagen in the cochlea in Alport syndrome. DESIGN: Case-control study. PATIENTS: Two patients with sensorineural hearing loss due to Alport syndrome. Both patients had known mutations in the COL4A5 gene. MAIN OUTCOME MEASURES: Immunostaining was used to study the distribution of type IV collagen (alpha1, alpha3, and alpha5 chains) within the cochlea. Immunostaining was also performed in the cochlear tissues of an unaffected individual used as a control. RESULTS: In the control ear, alpha1 staining was observed in the basement membrane overlying the basilar membrane, in the basement membrane of cochlear blood vessels and Schwann cells, and within the spiral limbus. In the control ear, we also observed strong staining for alpha3 and alpha5 chains in the basement membrane overlying the basilar membrane and within the spiral ligament. In both cases with Alport syndrome, no immunostaining was observed for alpha3 or alpha5 chains within the cochlea, whereas alpha1 staining was present in locations similar to that seen in the control ear. CONCLUSIONS: The results indicate that isotype switching does not occur within the cochlea in Alport syndrome. The results are also consistent with the hypothesis that the sensorineural hearing loss in Alport syndrome may be due to alterations in cochlear micromechanics and/or dysfunction of the spiral ligament.


Subject(s)
Cochlea/metabolism , Collagen Type IV/metabolism , Nephritis, Hereditary/metabolism , Adult , Basement Membrane/metabolism , Case-Control Studies , Cochlea/blood supply , Cochlea/cytology , Collagen Type IV/genetics , Coloring Agents , Eosine Yellowish-(YS) , Female , Fluorescent Dyes , Hearing Loss, Sensorineural/etiology , Hearing Loss, Sensorineural/metabolism , Hematoxylin , Humans , Male , Microscopy, Polarization , Middle Aged , Mutation/genetics , Nephritis, Hereditary/complications , Schwann Cells/metabolism
8.
Laryngoscope ; 115(1): 172-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15630389

ABSTRACT

OBJECTIVES: To elucidate factors that may be responsible for the inhibition of remodeling of bone within the otic capsule. METHODS: Expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK), and RANK ligand (RANKL) were assayed in samples of bone obtained from the otic capsule, calvarium, and femur, and from the soft tissue within the cochlea using semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) in mice. Immunostaining was used for histologic localization of the gene products. An enzyme-linked immunosorbent assay (ELISA) was used to quantify the amount of OPG within perilymph, serum, and cerebrospinal fluid. The micro-anatomy of the interface between the otic capsule and the fluid spaces of the cochlea was investigated by brightfield and phase-contrast microscopy and by three-dimensional reconstruction in the mouse and human. RESULTS: OPG, a powerful inhibitor of bone remodeling, was expressed at extremely high levels within the soft tissue of the cochlea and was present in the perilymph at very high concentrations. The OPG produced within the inner ear may diffuse into the surrounding otic capsule, where it may be responsible for inhibition of bone turnover. Our anatomic studies revealed an extensive system of interconnected canaliculi within the otic capsule that had direct openings into the fluid spaces of the inner ear, thus providing a possible anatomic route for the diffusion of OPG from the inner ear into the surrounding bone. CONCLUSION: OPG, a potent inhibitor of osteoclast formation and function, is expressed at high levels within the inner ear and is secreted into the perilymph and the surrounding bone and may serve to inhibit active bone remodeling within the otic capsule, especially immediately adjacent to the cochlea. By this means, the cochlear soft tissue may control the nature of the surrounding petrous bone.


Subject(s)
Bone Remodeling/physiology , Ear, Inner/chemistry , Glycoproteins/analysis , Receptors, Cytoplasmic and Nuclear/analysis , Temporal Bone/chemistry , Animals , Carrier Proteins/analysis , Cochlea/chemistry , Enzyme-Linked Immunosorbent Assay , Glycoproteins/blood , Glycoproteins/cerebrospinal fluid , Glycoproteins/physiology , Ligands , Membrane Glycoproteins/analysis , Mice , Mice, Inbred Strains , Osteoprotegerin , Perilymph/chemistry , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Receptors, Cytoplasmic and Nuclear/blood , Receptors, Cytoplasmic and Nuclear/physiology , Receptors, Tumor Necrosis Factor
9.
Otol Neurotol ; 25(4): 447-50, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15241219

ABSTRACT

HYPOTHESIS: There is an association between otosclerosis and osteoporosis. BACKGROUND: Both osteoporosis and otosclerosis are common bone diseases to which relatively large portions of the population are genetically predisposed. Recently, a strong association has been described between osteoporosis and an Sp1 binding site of putative functional significance in the first intron of the COL1A1 gene. METHODS: We applied polymerase chain reaction-based restriction enzyme analysis to determine the polymorphic distribution of the Sp1 site in 100 patients with otosclerosis and 108 control subjects. RESULTS: This study showed a significant association between otosclerosis and the COL1A1 first intron Sp1 site. The allelic frequency of the Sp1 site is very similar between otosclerosis and osteoporosis. CONCLUSION: Some cases of otosclerosis and osteoporosis could share a functionally significant polymorphism in the Sp1 transcription factor binding site in the first intron of the COL1A1 gene.


Subject(s)
Collagen Type I/genetics , Osteoporosis/genetics , Otosclerosis/genetics , Polymorphism, Genetic/genetics , Sp1 Transcription Factor/genetics , Aged , Aged, 80 and over , Binding Sites , Bone Density , Case-Control Studies , Collagen Type I/chemistry , Collagen Type I/physiology , Collagen Type I, alpha 1 Chain , Humans , Middle Aged , Polymerase Chain Reaction , Restriction Mapping , Sp1 Transcription Factor/chemistry
10.
Otol Neurotol ; 23(5): 789-92, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12218636

ABSTRACT

HYPOTHESIS: Contamination of archival human temporal bones with extraneous deoxyribonucleic acid may represent a potentially significant problem in the analysis of nucleic acids isolated from archival specimens. BACKGROUND: During the past decade, there has been growing interest in the development of molecular biologic techniques that can be applied to the investigation of pathologic changes in archival human temporal bones. The impetus for the development of these techniques is in part related to the fact that the temporal bone collections represent a repository of archival material compiled over decades, which is not available from living patients. METHODS: An archival human temporal bone specimen from a male patient with the Mohr-Tranebjaerg syndrome (formerly called DFN-1) and a well-characterized mutation was analyzed for the presence of the mutation by a standard method for extraction, isolation, amplification, and sequencing of deoxyribonucleic acid. The experiment was repeated four times. RESULTS: The deoxyribonucleic acid sequence from three of four extractions was normal. The known mutation was easily and repeatedly demonstrated in a blood sample from the same individual. Because Mohr-Tranebjaerg syndrome is X-linked, there is only one allele, and therefore there is no potential endogenous source to account for the normal sequence that was amplified. Contamination of the tissue sections by extraneous deoxyribonucleic acid presumably occurred during acquisition and processing of the temporal bone. CONCLUSIONS: Contamination of archival temporal bones with exogenous deoxyribonucleic acid is a significant potential problem that must be considered in the interpretation of the results of deoxyribonucleic acid retrieved from archival sections. The authors recommend collecting blood samples from temporal bone donors in the future to ensure the availability of a reliable source of deoxyribonucleic acid.


Subject(s)
Archives , DNA Damage/genetics , DNA/genetics , DNA/metabolism , Temporal Bone/metabolism , Aged , Culture Techniques , DNA Mutational Analysis , Humans , Male , Nucleic Acid Amplification Techniques , Orofaciodigital Syndromes/genetics
11.
Ann Otol Rhinol Laryngol ; 111(2): 184-9, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11860074

ABSTRACT

Because of the clinical and histopathologic similarities between otosclerosis and type I osteogenesis imperfecta, we examined COL1A1 messenger RNA (mRNA) expression in cultured fibroblasts from patients with clinical otosclerosis to determine whether abnormalities of expression of COL1A1 were present, as has been reported in type I osteogenesis imperfecta. Type I osteogenesis imperfecta has been found to result from mutations in the COL1A1 gene that result in null expression of the mutant allele. Patients with clinical otosclerosis were genotyped for the presence of an expressed 4 base-pair insertion polymorphism in the 3' region of the COL1A1 gene. Skin biopsies were performed, and cultured fibroblast cell lines were established from patients who were heterozygous for the polymorphism. Allelic expression was examined by reverse transcription-polymerase chain reaction and silver-stained polyacrylamide gel electrophoresis. Two of 9 patients with clinical otosclerosis demonstrated null or reduced expression of one COL1A1 allele. The differential expression of the two COL1A1 alleles in all subjects was also examined by a semiquantitative method using an ABI Prism 7700 Sequence Detection System (Taqman). We did this examination to determine whether milder abnormalities in COL1A1 expression might account for the development of otosclerosis in the 7 clinical cases that did not reveal evidence of null expression by the gel technique. Of the same 2 cases of otosclerosis that demonstrated evidence of null expression by gel electrophoresis, both were found to have significant differences in COL1A1 mRNA expression by the Taqman analysis. The remaining 7 cases revealed equal expression of the two COL1A1 alleles similar to that seen in controls. These results suggest that mutations in COL1A1 that are similar to those that occur in type I osteogenesis imperfecta may account for a small percentage of cases of otosclerosis, and that the majority of cases of clinical otosclerosis are related to other genetic abnormalities that have yet to be identified.


Subject(s)
Alleles , Collagen Type I/genetics , Osteogenesis Imperfecta/genetics , Otosclerosis/genetics , DNA, Complementary/analysis , Electrophoresis, Polyacrylamide Gel , Fibroblasts/chemistry , Gene Expression , Humans , Mutation , Polymerase Chain Reaction , Polymorphism, Genetic , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Skin/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...